· A deworming medicine for animals, fenbendazolehasnotbeen tested for use in humans as a cancer treatment. Get the facts about fenbendazole.
· In humans, other benzimidazoles, such as mebendazole and albendazole, are used as antiparasitic agents. However, fenbendazole is not currently approved by the FDA or EMA for human use, and its pharmacokinetics and safety in humans have yet to be well-documented in medical literature.
· A newly published study in Frontiers in Pharmacology (2025) looked at how fenbendazole, a drug traditionally used as an anti-parasitic, affects breastcancer cells in laboratory and animal models.
Fenbendazole is a benzimidazole anthelmintic agent commonly used to treat animal parasitic infections. In humans, other benzimidazoles, such as mebendazole and albendazole, are used as antiparasitic agents. Since fenbendazole is not currently approvedby the FDA or EMA, its pharmacokinetics and safety in humans have yet to be well-documented in medical literature. Despite this, insights can be ...
· Fenbendazole (a pet medicine) is being studied for breastcancer because it may stop cancer cells from growing while sparing healthy ones. Early research looks promising, especially for aggressive breastcancers, but it’s still experimental and not an approved treatment.
· While not yet approved for cancer treatment in humans, emerging preclinical studies reveal promising mechanisms by which fenbendazole may inhibit tumor growth and overcome drug resistance.
· Fenbendazole is not FDAapproved for cancer because there is no financial incentive to fund the huge human trials needed for approval. The drug is off-patent, inexpensive, and cannot be sold at monopoly prices.
